Measurement of Serum Chemerin and Deoxypyridinoline Levels in Iraqi Osteoporotic Postmenopausal Women with and without Metabolic Syndrome

Abstract

Metabolic syndrome is a cluster of medical conditions composed of abdominal obesity, hyperglycemia, hypertension, and lipid abnormalities, in which each can affect bone in different ways. We examine the association between metabolic syndrome and metabolic bone disease (osteoporosis) by measuring adipose tissue marker (chemerin) and bone resorption marker (deoxypyridinoline) in the serum of osteoporotic postmenopausal women with and without metabolic syndrome. A case-control study included 112 postmenopausal women from 51 to 67 years of age. Women were selected from Osteoporosis Clinic-Al Yarmouk Teaching Hospital and were divided into two groups: group (1)- patients group included 57 postmenopausal women with osteoporosis (35 osteoporotic women with metabolic syndrome and 22 osteoporotic women without metabolic syndrome) and group (2) - control group included 55 postmenopausal women without osteoporosis and metabolic syndrome. A serum sample was taken from each woman and analysed for assessing chemerin, deoxypyridinoline, fasting serum glucose, and lipid profile. We found a significant increase (p-value<0.001) in the mean value of serum chemerin and deoxypyridinoline levels in patients compared to controls. In conclusion, chemerin is an adipose tissue marker associated with metabolic syndrome and may have an impact on bone turn over and development of metabolic bone disease which enhanced by the strong positive correlation between chemerin and bone resorption marker (deoxypyridinoline).